Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?

被引:32
作者
Chakrabarti, S
Handa, SK
Bryon, RJ
Griffiths, MJ
Milligan, DW [1 ]
机构
[1] Birmingham Heartlands Hosp, Dept Haematol, Birmingham B9 5SS, W Midlands, England
[2] Sandwell Gen Hosp, Dept Haematol, Birmingham, W Midlands, England
[3] Birmingham Womens Hosp, Reg Genet Lab, Birmingham, W Midlands, England
关键词
D O I
10.1097/00007890-200107270-00032
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Mixed chimerism after allogeneic bone marrow transplantation has been shown to cure a number of genetic disorders in both the clinical and experimental settings. Although encouraging results have been reported from animal experiments, the role of mixed chimerism. in eliminating autoimmune disorders is not clear. Methods. A 50-year-old man with extensive psoriasis received an allogeneic transplant from his brother after nonmyeloablative conditioning with fludarabine, melphalan, and Campath-1H for relapsed non-Hodgkin's lymphoma. The chimerism status and the immunological recovery after the transplant were serially monitored. Results. Twenty-one months after the transplant, the patient continues to be in complete remission from psoriasis and lymphoma with stable mixed chimerism (30% to 40% donor cells), despite significant recovery of T-cell subsets and antigen-specific response. Conclusions. If mixed chimerism can be achieved safely with novel low-intensity conditioning regimens and results in sustained remission of autoimmune diseases, allogeneic transplantation may become a realistic therapy in the management of some patients with autoimmune disease.
引用
收藏
页码:340 / 342
页数:3
相关论文
共 11 条
[1]   Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by Sca-1+Lin- bone marrow progenitor cells:: Synergism with non-alloreactive (Host x Donor)F1 T cells [J].
Bachar-Lustig, E ;
Li, HW ;
Gur, H ;
Krauthgamer, R ;
Marcus, H ;
Reisner, Y .
BLOOD, 1999, 94 (09) :3212-3221
[2]   Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat - A relationship between allo- and autoimmunity [J].
Delaney, CP ;
Murase, N ;
ChenWoan, M ;
Fung, JJ ;
Starzl, TE ;
Demetris, AJ .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (01) :217-225
[3]   EMERGENCE OF OLIGOCLONAL T-CELL POPULATIONS FOLLOWING THERAPEUTIC T-CELL DEPLETION IN RHEUMATOID-ARTHRITIS [J].
JENDRO, MC ;
GANTEN, T ;
MATTESON, EL ;
WEYAND, CM ;
GORONZY, JJ .
ARTHRITIS AND RHEUMATISM, 1995, 38 (09) :1242-1251
[4]  
Li H, 1996, J IMMUNOL, V156, P380
[5]   Course of Crohn's disease after allogeneic marrow transplantation [J].
Lopez-Cubero, SO ;
Sullivan, KM ;
McDonald, GB .
GASTROENTEROLOGY, 1998, 114 (03) :433-440
[6]   The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia [J].
Lowdell, MW ;
Craston, R ;
Ray, N ;
Koh, M ;
Galatowicz, G ;
Prentice, HG .
BONE MARROW TRANSPLANTATION, 1998, 21 (07) :679-686
[7]  
McSweeney P A, 1999, Biol Blood Marrow Transplant, V5, P192, DOI 10.1053/bbmt.1999.v5.pm10465099
[8]  
Snowden JA, 1998, ARTHRITIS RHEUM, V41, P453, DOI 10.1002/1529-0131(199803)41:3<453::AID-ART11>3.3.CO
[9]  
2-R
[10]   Autologous haematopoietic stem cell transplants for autoimmune disease -: feasibility and transplant-related mortality [J].
Tyndall, A ;
Fassas, A ;
Passweg, J ;
de Elvira, CR ;
Attal, M ;
Brooks, P ;
Black, C ;
Durez, P ;
Finke, J ;
Forman, S ;
Fouillard, L ;
Furst, D ;
Holmes, JA ;
Joske, D ;
Jouet, JP ;
Kötter, I ;
Locatelli, F ;
Prentice, HG ;
Marmont, AM ;
McSweeney, P ;
Musso, M ;
Peter, HH ;
Snowden, JA ;
Sullivan, K ;
Tichelli, A ;
Vavriec, J ;
Wulffraat, NM ;
Schmitz, N ;
Gratwohl, A .
BONE MARROW TRANSPLANTATION, 1999, 24 (07) :729-734